[Source](https://github.com/mm80843/T3.5/blob/main/docs/index.md) -- [Benef](https://github.com/mm80843/T3.5/tree/main/docs/Benef/index.md) 

# Benef: __Tracking antimicrobial usage__ (PBN__Benef_217)

## Property: has_Beneficiary

* [pharmaceutical companies](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_124.md)
* [healthcare providers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_121.md)

## Property: has_BenefSource

* [sims_future_2020](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_48.md)

## Property: has_BenefReturn

* [Private investors investing in this mitigation measure could benefit from improved asset value by supporting the development of targeted antimicrobial therapies and reducing the misuse of antimicrobials, leading to improved patient outcomes and decreased healthcare costs.](https://github.com/mm80843/T3.5/blob/main/docs/BenefReturn/PBN__BenefReturn_224.md)

## Property: has_BenefDetails

Allows for the monitoring of antimicrobial usage at a community-wide level to identify trends and provide accurate data on consumption patterns

